PBI: Brachytherapy Techniques

Chapter

Abstract

For 110 years, there has been a tradition of treating the entire breast for all breast cancers, regardless of stage or how early they were detected. Sir William Halstead proposed the original hypothesis that the entire organ needed to be treated and that the treatment field must include all possible extensions of the malignancy, including nodal regions. Mastectomy has since given way to lumpectomy. Whole breast radiotherapy may similarly not be necessary for all patients needing post-lumpectomy radiotherapy. Brachytherapy techniques were the first to demonstrate ‘proof of principle’ for accelerated, partial breast irradiation. This chapter provides an overview of accelerated, partial breast irradiation using interstitial brachytherapy, which usually delivers treatment BID over 5 days rather than the 6 to 6 ½ weeks needed for whole breast radiotherapy.

Keywords

Catheter Coumadin Sponge Epinephrine Lidocaine 

References

  1. 1.
    Morrow M, Harris JR. Local management of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams; 2000. p. 528.Google Scholar
  2. 2.
    Fisher B, Anderson S, Bryant J, et al. Twenty year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233.PubMedCrossRefGoogle Scholar
  3. 3.
    Holland R, Veling SH, Mravunac M, et al. Histologic multifocality of Tis T1-2 breast carcinomas: implications for clinical trials of breast conserving surgery. Cancer. 1985;56:979–90.CrossRefGoogle Scholar
  4. 4.
    Vicini FA, Baglan K, Kestin L, et al. The emerging role of brachytherapy in the management of patients with breast cancer. Semin Radiat Oncol. 2002;12:31–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Kuske RR, Boyer C, Bolton JS, et al. Long-term results of the Ochsner Clinic prospective phase II breast brachytherapy trial. In: 27th Annual San Antonio Breast Cancer Symposium, San Antonio, 2004.Google Scholar
  6. 6.
    Kuske RR, Winter K, Arthur D, et al. A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 95-17. In: American Society of Clinical Oncology, Alexandria; 2004.Google Scholar
  7. 7.
    King TA, Bolton JS, Kuske RR, et al. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T(is, 1, 2) breast cancer. Am J Surg. 2000;180:299–304.PubMedCrossRefGoogle Scholar
  8. 8.
    Baglan KL, Martinez AA, Frazier RC, et al. The use of high-dose brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2001;50:1003–2010.PubMedCrossRefGoogle Scholar
  9. 9.
    Keynes G. Conservative treatment of cancer of the breast. Br Med J. 1937;2:643.PubMedCrossRefGoogle Scholar
  10. 10.
    Pallet DJ, Kuske RR, Quiet CA, et al. Infection management in patients treated with breast brachytherapy. Semin Breast Dis. 2007;10(1):34–6.CrossRefGoogle Scholar
  11. 2010.
    Vicini FA, Beitch P, Quiet CA, et al. In: Proceedings of ASCO, Journal of Clinical Oncology, vol 24 No. 18s; 2006. p. 529.Google Scholar
  12. 12.
    Edmundson GK, Vicini FA, Chen PY, et al. Dosimetric characteristics of the MammoSite RTS: a new breast brachytherapy applicator. Int J Radiat Oncol Biol Phys. 2002;52:201032–9.CrossRefGoogle Scholar
  13. 13.
    Patel R, et al. Presented at the 3rd Annual School of Breast Brachytherapy, Las Vegas, NV, March 2005.Google Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  1. 1.Arizona Breast Cancer SpecialistsScottsdaleAZUSA

Personalised recommendations